{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:38:28Z","timestamp":1792175908982,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112954"],"award-info":[{"award-number":["70112954"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["BMBF 01ZZ1804C"],"award-info":[{"award-number":["BMBF 01ZZ1804C"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201806010411"],"award-info":[{"award-number":["201806010411"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105913","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:41:32Z","timestamp":1763757692000},"page":"105913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7646-5661","authenticated-orcid":false,"given":"G.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7895-8396","authenticated-orcid":false,"given":"H.","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5642-1316","authenticated-orcid":false,"given":"L.","family":"Mishieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-2345","authenticated-orcid":false,"given":"S.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Christgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Christgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.D.","family":"Kandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-6209","authenticated-orcid":false,"given":"M.","family":"Raap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-7544","authenticated-orcid":false,"given":"O.","family":"Gluz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-717X","authenticated-orcid":false,"given":"M.","family":"Graeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9355-494X","authenticated-orcid":false,"given":"S.","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Nitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2554-3952","authenticated-orcid":false,"given":"C.","family":"Plass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-8906","authenticated-orcid":false,"given":"U.","family":"Mansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"zu Eulenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5792-3901","authenticated-orcid":false,"given":"C.","family":"Gerh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Kreipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2025.105913_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105913_bib2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105913_bib3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1677\/erc.1.00857","article-title":"Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer","volume":"12","author":"Normanno","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105913_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care (Basel)"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105913_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105913_bib6","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2- early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105913_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10549-008-9897-4","article-title":"Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance","volume":"112","author":"Harvell","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105913_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10549-018-4933-5","article-title":"Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling","volume":"172","author":"Goto-Yamaguchi","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"27","key":"10.1016\/j.esmoop.2025.105913_bib10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"24 Pt 1","key":"10.1016\/j.esmoop.2025.105913_bib11","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1158\/1078-0432.CCR-05-0735","article-title":"Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes","volume":"11","author":"Cobleigh","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105913_bib12","doi-asserted-by":"crossref","first-page":"e177813","DOI":"10.1172\/JCI177813","article-title":"A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders","volume":"135(19)","author":"Zhang","year":"2025","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105913_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105913_bib14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105913_bib15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1078-0432.CCR-22-1587","article-title":"Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT HER2+\/HR- trial","volume":"29","author":"Graeser","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105913_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based Prosigna breast cancer gene signature assay","volume":"8(1)","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.esmoop.2025.105913_bib17","author":"Bl\u00f6tner"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105913_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005752","article-title":"mixOmics: an R package for \u2019omics feature selection and multiple data integration","volume":"13","author":"Rohart","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.esmoop.2025.105913_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1471-2105-12-253","article-title":"Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems","volume":"12(1)","author":"L\u00ea Cao","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.esmoop.2025.105913_bib20","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","article-title":"Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer","volume":"19","author":"Gy\u0151rffy","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105913_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100100","article-title":"P53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance","volume":"36","author":"Mueller","year":"2023","journal-title":"Mod Pathol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105913_bib22","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1002\/cam4.4376","article-title":"TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer","volume":"10","author":"Grote","year":"2021","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105913_bib23","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s12094-024-03777-x","article-title":"Menopausal status-dependent alterations in the transcript levels of genes encoding ER\u03b1, ER\u03b2, PR and HER2 in breast tumors with different receptor status","volume":"27","author":"Berkel","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105913_bib24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jnci\/dji249","article-title":"Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance","volume":"97","author":"Arpino","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"30","key":"10.1016\/j.esmoop.2025.105913_bib25","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1200\/JCO.2005.09.004","article-title":"Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy","volume":"23","author":"Cui","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.esmoop.2025.105913_bib26","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1200\/JCO.2007.12.2747","article-title":"Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype","volume":"25","author":"Rakha","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105913_bib27","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"issue":"7403","key":"10.1016\/j.esmoop.2025.105913_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition","volume":"486","author":"Ellis","year":"2012","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105913_bib29","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1158\/1078-0432.CCR-20-1923","article-title":"Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients","volume":"26","author":"Schroth","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105913_bib30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1634\/theoncologist.2015-0369","article-title":"Deciphering and targeting oncogenic mutations and pathways in breast cancer","volume":"21","author":"Santarpia","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105913_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/BST20190778","article-title":"PI3K in stemness regulation: from development to cancer","volume":"48","author":"Madsen","year":"2020","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105913_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009876","article-title":"Positive correlation between transcriptomic stemness and PI3K\/AKT\/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype","volume":"17","author":"Madsen","year":"2021","journal-title":"PLoS Genet"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105913_bib33","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1158\/1078-0432.CCR-08-1763","article-title":"Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer","volume":"15","author":"Gonzalez-Angulo","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105913_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105080","article-title":"Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysis","volume":"10","author":"Sinberger","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105913_bib35","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/JCO.2017.74.8301","article-title":"Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data","volume":"36","author":"Zardavas","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105913_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10549-024-07545-x","article-title":"Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers","volume":"210","author":"Hanf","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105913_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3727\/105221615X14399878166113","article-title":"GATA3 in breast cancer: tumor suppressor or oncogene?","volume":"16","author":"Takaku","year":"2015","journal-title":"Gene Expr"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105913_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183656","article-title":"MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer","volume":"135","author":"Cai","year":"2024","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105913_bib39","doi-asserted-by":"crossref","first-page":"13738","DOI":"10.18632\/aging.205260","article-title":"Involvement of RFC3 in tamoxifen resistance in ER-positive breast cancer through the cell cycle","volume":"15","author":"Zhu","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105913_bib40","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/1541-7786.MCR-19-1082","article-title":"The NF-\u03baB pathway promotes tamoxifen tolerance and disease recurrence in estrogen receptor-positive breast cancers","volume":"18","author":"Kastrati","year":"2020","journal-title":"Mol Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105913_bib41","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/ijc.33054","article-title":"The role of CDK6 in cancer","volume":"147","author":"Nebenfuehr","year":"2020","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105913_bib42","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1158\/0008-5472.CAN-22-2525","article-title":"Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer","volume":"83","author":"Malik","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105913_bib43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrc3920","article-title":"Mechanisms of aromatase inhibitor resistance","volume":"15","author":"Ma","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105913_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105913_bib45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105913_bib46","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105913_bib47","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6577","key":"10.1016\/j.esmoop.2025.105913_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105913_bib49","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105913_bib50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.annonc.2020.11.022","article-title":"Immunotherapy for early breast cancer: too soon, too superficial, or just right?","volume":"32","author":"Franzoi","year":"2021","journal-title":"Ann. Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105913_bib51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1078-0432.CCR-21-2260","article-title":"Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial","volume":"28","author":"Dieci","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105913_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5952836","article-title":"TP53 mutations promote immunogenic activity in breast cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"J Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105913_bib53","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105913_bib54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jnci\/85.3.200","article-title":"Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer","volume":"85","author":"Allred","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105913_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105913_bib56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105913_bib57","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105913_bib58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer","volume":"523(7560)","author":"Mohammed","year":"2015","journal-title":"Nature"},{"issue":"15_suppl","key":"10.1016\/j.esmoop.2025.105913_bib59","doi-asserted-by":"crossref","first-page":"e11566","DOI":"10.1200\/jco.2015.33.15_suppl.e11566","article-title":"Prognostic effect of PgR in luminal type breast cancer","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105913_bib60","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.2007.10.6393","article-title":"Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors\u2014International Breast Cancer Study Group","volume":"26","author":"Viale","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105913_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.813462","article-title":"Prognostic relevance of progesterone receptor levels in early luminal-like HER2 negative breast cancer subtypes: a retrospective analysis","volume":"12","author":"Diana","year":"2022","journal-title":"Front Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:49:47Z","timestamp":1778834987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017831"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105913","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105913"}}